review
studi
attempt
answer
whether
necessari
includ
antibiot
activ
atyp
pneumonia
agent
part
empir
therapi
cap
lack
data
random
trial
question
answer
use
sever
strategi
indic
frequenc
atyp
agent
caus
pneumonia
ambulatori
hospit
patient
cap
provid
overview
epidemiolog
outcom
data
pneumonia
caus
four
atyp
pathogen
name
pneumonia
l
pneumophila
chlamydia
pneumonia
coxiella
burnetii
consid
data
observ
studi
pneumonia
caus
agent
consid
data
larg
retrospect
studi
cap
etiolog
agent
commonli
caus
communityacquir
pneumonia
although
surprisingli
studi
attempt
defin
etiolog
cap
treat
ambulatori
basi
consist
pictur
emerg
etiolog
undefin
case
pneumonia
commonli
identifi
agent
follow
chlamydia
pneumonia
streptococcu
pneumonia
haemophilu
influenza
staphylococcu
aureu
l
pneumophila
mani
studi
defin
etiolog
cap
among
patient
requir
admiss
hospit
mani
countri
imposs
defin
etiolog
mani
patient
streptococcu
pneumonia
commonli
identifi
pathogen
set
depend
method
use
implic
caus
cap
patient
requir
admiss
hospit
chlamydia
pneumonia
commonli
identifi
atyp
agent
patient
pneumonia
less
common
patient
ambulatori
pneumonia
still
implic
substanti
number
one
studi
legionella
speci
common
among
patient
requir
admiss
intens
care
overal
account
approxim
patient
requir
admiss
hospit
treatment
cap
unfortun
studi
captur
pathogen
may
occur
local
outbreak
hantaviru
pathogen
occur
worldwid
outbreak
short
durat
sar
coronaviru
studi
diagnosi
pneumonia
l
pneumophila
chlamydia
pneumonia
made
use
serolog
criteria
posit
test
huge
impact
number
case
diagnos
fourfold
increas
antibodi
titer
acut
convalesc
serum
sampl
gener
consid
definit
evid
infect
test
agent
occur
high
singl
stabl
titer
often
consid
diagnost
well
howev
one
studi
incid
pneumonia
per
popul
criteria
definit
infect
use
per
titer
higher
use
studi
fourfold
increas
singletit
criteria
appli
incid
chlamydia
pneumonia
per
per
respect
l
pneumophila
per
per
respect
mycoplasma
includ
pneumonia
smallest
freeliv
organ
size
lm
similar
myxovirus
genom
pneumonia
consist
base
pair
sequenc
entireti
adher
host
respiratori
epitheli
cell
mediat
protein
locat
tiplik
organel
pneumonia
pneumonia
adher
mucou
ciliat
epitheli
cell
respiratori
tract
chemotact
stimulu
lead
direct
motil
mycoplasma
base
cilia
protect
mycoplasma
clearanc
action
ciliari
system
hour
contact
loss
ciliari
motil
observ
follow
extens
damag
host
cell
like
ciliari
stasi
cell
damag
result
product
hydrogen
peroxid
superoxid
pneumonia
pneumonia
manifest
pneumonia
infect
frequent
recogn
clinician
incub
period
week
onset
gradual
retrospect
review
pneumonia
pneumonia
case
mayo
clinic
period
mansel
colleagu
report
patient
cough
common
symptom
occur
follow
fever
fiftytwo
percent
patient
sore
throat
rhinorrhea
chest
pain
complain
dyspnea
symptom
includ
nausea
vomit
diarrhea
anorexia
headach
chill
myalgia
arthralgia
night
sweat
seven
percent
one
symptom
neurolog
diseas
includ
diplopia
syncop
confus
tinnitu
one
patient
sever
hemoptysi
follow
find
note
physic
examin
pharyng
erythema
pulmonari
consolid
cervic
lymphadenopathi
otiti
media
bullou
myring
skin
lesion
mortal
uncommon
patient
pneumonia
illustr
studi
marri
colleagu
patient
requir
admiss
hospit
treatment
pneumonia
pneumonia
die
patient
termin
shydrag
syndrom
die
diseas
pneumonia
ali
studi
patient
dieda
woman
syndrom
admit
multilob
pneumonia
hemolyt
anemia
die
hour
admiss
lind
report
fatal
case
pneumonia
pneumonia
describ
chan
welsh
perform
review
fulmin
pneumonia
pneumonia
found
case
divid
three
categori
nonfat
respiratori
failur
case
fatal
case
respiratori
failur
case
fatal
case
without
respiratori
failur
seven
case
one
noteworthi
featur
pneumonia
infect
varieti
extrapulmonari
infect
almost
organ
system
involv
seri
patient
pneumonia
infect
extrapulmonari
manifest
antimicrobi
suscept
pneumonia
determin
agar
dilut
broth
dilut
method
usual
form
metabol
inhibit
test
use
method
pneumonia
suscept
macrolid
tetracyclin
quinolon
streptomycin
pristinamycin
ketolid
erythromycinresist
strain
pneumonia
isol
treat
patient
resist
result
point
mutat
gene
shame
colleagu
evalu
respons
therapi
militari
traine
pneumonia
pneumonia
note
patient
treat
demeclocyclin
declomycin
febril
day
compar
day
treat
tetracyclin
achromycin
v
erythromycin
stearat
erythrocin
control
subject
febril
day
mean
durat
hospit
day
day
demeclocyclin
tetracyclin
respect
versu
day
control
subject
treat
erythromycin
stearat
hospit
mean
day
treat
erythromycin
ethyl
succin
ee
hospit
mean
day
investig
also
note
clinic
cure
equat
erad
pneumonia
respiratori
tract
followup
control
subject
cultureposit
pneumonia
compar
subject
treat
variou
antibiot
kingston
colleagu
treat
patient
pneumonia
pneumonia
demethylchlortetracyclin
patient
placebo
mean
number
day
treat
patient
oral
temperatur
f
day
versu
day
placebotr
group
pneumonia
infect
tend
peak
everi
year
outbreak
occur
school
militari
base
summer
camp
juli
annual
convent
american
legion
held
hotel
philadelphia
one
hundr
eightytwo
attende
convent
develop
pneumonia
one
hundr
fortyseven
hospit
die
outbreak
pneumonia
appar
unknown
caus
trigger
exhaust
epidemiolog
microbiolog
investig
center
diseas
control
prevent
cdc
culmin
isol
new
microorgan
legionella
pneumophila
approxim
month
later
year
initi
outbreak
case
sporad
legionnair
diseas
ld
diagnos
unit
state
case
occur
june
octob
patient
male
white
week
onset
ill
travel
overnight
visit
hospit
hospit
day
onset
ill
twentythre
percent
live
within
sight
construct
excav
site
expos
construct
excav
marston
colleagu
analyz
legionella
surveil
data
patient
report
cdc
diseas
rate
vari
year
higher
northern
state
summer
mean
age
patient
ld
year
compar
year
unit
state
popul
contrast
earlier
report
person
ld
like
nonwhit
also
like
smoker
diabet
cancer
aid
endstag
renal
diseas
observ
number
case
among
patient
aid
higher
expect
risk
factor
mortal
studi
marston
colleagu
includ
older
age
male
sex
nosocomi
acquisit
diseas
immunosuppress
endstag
renal
diseas
cancer
twentythre
percent
case
acquir
nosocomi
two
recent
larg
outbreak
ld
taught
addit
lesson
fascin
diseas
explos
outbreak
ld
occur
murcia
spain
juli
suspect
case
confirm
ld
noteworthi
low
mortal
rate
outbreak
caus
contamin
cool
tower
case
occur
km
downwind
major
outbreak
occur
march
netherland
flower
show
person
attend
flower
show
develop
ld
sourc
outbreak
contamin
decor
fountain
outbreak
allow
investig
determin
risk
factor
intens
care
unit
icu
admiss
death
impact
adequ
therapi
icu
surviv
hospit
patient
icu
mortal
overal
mortal
start
adequ
therapi
within
hour
admiss
associ
significantli
higher
icu
surviv
versu
start
therapi
hour
admiss
find
appli
patient
neg
urinari
antigen
suggest
bacteri
load
play
role
outcom
heath
colleagu
studi
patient
ld
communityacquir
found
mortal
rate
investig
note
survivor
therapi
erythromycin
start
median
day
onset
symptom
compar
day
onset
die
although
initi
recommend
treatment
ld
highdos
intraven
erythromycin
edelstein
found
azithromycin
zithromax
activ
intracellular
l
pneumophila
erythromycin
recommend
treatment
ld
fluoroquinolon
contrast
erythromycin
kill
intracellular
legionella
azithromycin
plouff
colleagu
openlabel
studi
treat
hospit
patient
ld
overal
cure
rate
among
clinic
evalu
patient
grayston
colleagu
describ
new
chlamydia
speci
caus
respiratori
tract
infect
organ
later
name
chlamydia
pneumonia
subsequ
studi
shown
microorgan
implic
frequent
caus
cap
mani
care
studi
chlamydia
pneumonia
sole
caus
pneumonia
almiral
colleagu
studi
patient
cap
found
chlamydia
pneumonia
pneumonia
seven
copathogen
demonstr
includ
adenoviru
three
parainfluenza
viru
two
l
pneumophila
one
respiratori
syncyti
viru
one
file
colleagu
found
patient
chlamydia
pneumonia
pneumonia
copathogen
marri
colleagu
studi
patient
cap
requir
hospit
found
acut
chlamydia
pneumonia
infect
addit
possibl
acut
infect
mortal
rate
patient
chlamydia
pneumonia
lower
patient
infect
result
studi
led
question
import
c
pneumonia
caus
cap
random
trial
evalu
treatment
chlamydia
pneumonia
pneumonia
coxiella
burnetii
q
fever
pneumonia
q
fever
zoonosi
describ
outbreak
febril
ill
among
abattoir
worker
brisban
australia
q
fever
usual
transmit
aerosol
gener
parturit
infect
anim
cattl
sheep
goat
usual
reservoir
cat
dog
pigeon
also
infect
serv
sourc
outbreak
infect
infect
may
acut
selflimit
fever
pneumonia
hepat
central
nervou
system
infect
chronic
endocard
hepat
osteomyel
intravascular
infect
q
fever
account
approxim
ambulatori
pneumonia
endem
area
gener
tetracyclin
quinolon
rifampin
rifadin
telithromycin
ketek
clarithromycin
biaxin
activ
coxiella
burnetii
strain
suscept
erythromycin
other
sobradillo
colleagu
perform
prospect
random
doubleblind
studi
doxycyclin
doryx
erythromycin
treatment
patient
q
fever
pneumonia
twentythre
patient
receiv
doxycyclin
mg
twice
daili
receiv
erythromycin
mg
everi
hour
day
resolut
fever
occur
rapidli
doxycyclinetr
group
ae
day
versu
ae
day
erythromycintr
patient
p
day
chest
radiograph
normal
patient
kuzman
colleagu
studi
patient
q
fever
pneumonia
treat
patient
azithromycin
total
dose
g
administ
day
doxycyclin
mg
twice
day
day
varieti
antibiot
azithromycintr
group
fever
mean
day
doxycyclinetr
group
day
patient
receiv
antibiot
day
kofterid
colleagu
retrospect
review
patient
q
fever
pneumonia
note
patient
treat
tetracyclin
becam
afebril
mean
day
patient
treat
erythromycin
afebril
mean
day
patient
treat
blactam
agent
requir
day
becom
afebril
fifteen
percent
clarithromycintr
patient
febril
day
compar
erythromycintr
patient
none
tetracyclinetr
patient
retrospect
review
patient
q
fever
pneumonia
patient
treat
erythromycin
eight
blactam
antibiot
erythromycintr
group
afebril
day
wherea
two
blactamtr
group
afebril
day
p
although
evid
spars
seem
treatment
choic
q
fever
pneumonia
doxycyclin
day
altern
therapi
fluoroquinolon
macrolid
plu
rifampin
rifadin
substitut
glu
ly
posit
correspond
amino
acid
escherichia
coli
result
quinolon
resist
coxiella
burnetii
realtim
polymeras
chain
reaction
assay
use
murin
macrophag
cell
line
day
treatment
tetracyclin
rifampin
ampicillin
amoxil
significantli
inhibit
replic
coxiella
burnetii
wherea
chloramphenicol
chloromycetin
ciprofloxacin
observ
studi
regard
ampicillin
fit
clinic
observ
outlin
possibl
strain
use
resist
ciprofloxacin
one
contend
atyp
agent
caus
ambulatori
cap
treatment
choic
would
macrolid
doxycyclin
streptococcu
pneumonia
major
caus
ambulatori
pneumonia
howev
incid
pneumococc
macrolid
resist
unit
state
doubl
current
approxim
pneumococc
isol
resist
erythromycin
would
leav
amoxicillin
new
fluoroquinolon
firstlin
therapi
ambulatori
cap
cdc
work
group
recommend
use
fluoroquinolon
case
fail
agent
howev
concern
emerg
fluoroquinoloneresist
streptococcu
pneumonia
north
america
efflux
mechan
wherebi
streptococcu
pneumonia
resist
penicillin
presum
newer
macrolid
clarithromycin
azithromycin
overcom
europ
macrolid
resist
result
targetsit
alter
henc
absolut
therefor
reason
differ
recommend
firstlin
therapi
ambulatori
cap
north
america
europ
possibl
ketolid
becom
agent
choic
treatment
ambulatori
cap
side
atlant
doubleblind
random
control
trial
compar
amoxicillin
telithromycin
need
determin
optim
agent
treatment
ambulatori
cap
pneumonia
requir
hospit
data
larg
retrospect
studi
observ
studi
oosterheert
colleagu
perform
systemat
review
determin
evid
current
recommend
empir
antimicrobi
therapi
patient
hospit
cap
includ
origin
peerreview
articl
publish
januari
april
regard
adult
patient
hospit
cap
deal
question
whether
treatment
blactam
plu
macrolid
quinolon
monotherapi
reduc
mortal
length
stay
compar
blactam
treatment
alon
found
eight
articl
met
criteria
inclus
six
studi
found
signific
reduct
mortal
patient
treat
combin
blactam
plu
macrolid
fluoroquinolon
alon
three
six
studi
involv
patient
bacterem
pneumococc
pneumonia
exclus
mortal
reduc
combin
macrolid
blactam
two
eight
studi
reduc
length
stay
note
patient
treat
macrolid
combin
anoth
agent
attribut
favor
effect
macrolid
combin
coverag
atyp
agent
one
studi
prospect
leveliii
evid
benefici
effect
combin
therapi
blactam
macrolid
may
found
random
trial
bjerr
colleagu
set
summar
evid
random
clinic
trial
concern
efficaci
antibiot
treatment
cap
ambulatori
patient
year
age
older
comprehens
search
identifi
relev
studi
thirtyfour
articl
met
screen
criteria
three
trial
met
inclus
criteria
three
trial
involv
patient
none
three
studi
clearli
state
random
method
two
trial
involv
comparison
clarithromycin
erythromycin
sparfloxacin
zagam
versu
clarithromycin
thu
none
three
suitabl
answer
question
import
therapi
direct
atyp
agent
nevertheless
author
metaanalysi
conclud
current
evid
random
clinic
trial
insuffici
make
evidencebas
recommend
choic
antibiot
use
treatment
cap
ambulatori
patient
data
proper
studi
answer
whether
necessari
includ
antibiot
activ
atyp
pneumonia
agent
part
empir
therapi
cap
data
avail
clinic
judgment
sever
pneumon
ill
best
guid
empir
antimicrobi
therapi
